[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100572244":3},{"organization":4,"armGroups":7,"interventions":27,"overallOfficials":36,"centralContacts":39,"locations":47,"responsibleParty":122,"collaborators":11,"id":124,"slug":11,"hasResults":125,"nctId":126,"briefTitle":127,"officialTitle":128,"acronym":11,"eligibilityCriteria":129,"healthyVolunteers":125,"sex":130,"minAge":131,"maxAge":11,"enrollmentInfo":132,"targetDuration":11,"studyType":135,"phases":136,"briefSummary":139,"conditions":140,"keywords":142,"overallStatus":93,"whyStopped":11,"lastUpdateSubmitDate":146,"lastUpdatePostDateStruct":147,"startDateStruct":150,"completionDateStruct":152,"leadSponsor":154,"locationsCount":155},{"fullName":5,"class":6},"Bristol-Myers Squibb","INDUSTRY",[8,14,17,20,24],{"label":9,"type":10,"description":11,"interventionNames":12},"Part 1A","EXPERIMENTAL",null,[13],"Drug: BMS-986490",{"label":15,"type":10,"description":11,"interventionNames":16},"Part 2A - Colorectal Cancer (CRC)",[13],{"label":18,"type":10,"description":11,"interventionNames":19},"Part 2A - Non-Small Cell Lung Cancer\u002FGastric Cancer (NSCLC\u002FGC)",[13],{"label":21,"type":10,"description":11,"interventionNames":22},"Part 1B",[13,23],"Drug: Bevacizumab",{"label":25,"type":10,"description":11,"interventionNames":26},"Part 2B",[13,23],[28,33],{"type":29,"name":30,"description":31,"armGroupLabels":32,"otherNames":11},"DRUG","BMS-986490","Specified dose on specified days.",[9,21,15,18,25],{"type":29,"name":34,"description":31,"armGroupLabels":35,"otherNames":11},"Bevacizumab",[21,25],[37],{"name":5,"affiliation":5,"role":38},"STUDY_DIRECTOR",[40,45],{"name":41,"role":42,"phone":43,"phoneExt":11,"email":44},"BMS Clinical Trials Contact Center www.BMSClinicalTrials.com","CONTACT","855-907-3286","Clinical.Trials@bms.com",{"name":46,"role":42,"phone":11,"phoneExt":11,"email":11},"First line of the email MUST contain NCT # and Site #.",[48,61,71,81,91,107],{"facility":49,"status":50,"city":51,"state":52,"zip":53,"country":54,"cosmosGeoPoint":55,"geoPoint":60,"contacts":11},"Local Institution - 0007","ACTIVE_NOT_RECRUITING","Los Angeles","California","90033","United States",{"type":56,"coordinates":57},"Point",[58,59],-118.24368,34.05223,{"lat":59,"lon":58},{"facility":62,"status":50,"city":63,"state":64,"zip":65,"country":54,"cosmosGeoPoint":66,"geoPoint":70,"contacts":11},"Local Institution - 0017","Grand Rapids","Michigan","49546",{"type":56,"coordinates":67},[68,69],-85.66809,42.96336,{"lat":69,"lon":68},{"facility":72,"status":50,"city":73,"state":74,"zip":75,"country":54,"cosmosGeoPoint":76,"geoPoint":80,"contacts":11},"Local Institution - 0004","Hackensack","New Jersey","07601",{"type":56,"coordinates":77},[78,79],-74.04347,40.88593,{"lat":79,"lon":78},{"facility":82,"status":50,"city":83,"state":84,"zip":85,"country":54,"cosmosGeoPoint":86,"geoPoint":90,"contacts":11},"Local Institution - 0006","Pittsburgh","Pennsylvania","15232",{"type":56,"coordinates":87},[88,89],-79.99589,40.44062,{"lat":89,"lon":88},{"facility":92,"status":93,"city":94,"state":95,"zip":96,"country":97,"cosmosGeoPoint":98,"geoPoint":102,"contacts":103},"Tasman Oncology Research","RECRUITING","Southport","Queensland","4215","Australia",{"type":56,"coordinates":99},[100,101],153.39796,-27.96724,{"lat":101,"lon":100},[104],{"name":105,"role":42,"phone":106,"phoneExt":11,"email":11},"Andrew Hill, Site 0012","+61756132480",{"facility":108,"status":93,"city":109,"state":110,"zip":111,"country":112,"cosmosGeoPoint":113,"geoPoint":117,"contacts":118},"Princess Margaret Cancer Centre","Toronto","Ontario","M5G 2M9","Canada",{"type":56,"coordinates":114},[115,116],-79.39864,43.70643,{"lat":116,"lon":115},[119],{"name":120,"role":42,"phone":121,"phoneExt":11,"email":11},"Anna Spreafico, Site 0003","4169464501",{"type":123,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100572244",false,"NCT06730750","A Study of BMS-986490 With or Without Bevacizumab in Advanced Solid Tumors","A Phase 1\u002F2a, Multicenter, Open-label, First in Human Study of BMS-986490 With or Without Bevacizumab in Advanced Solid Tumors","Inclusion Criteria:\n\n* Documented histologically or cytologically confirmed, advanced, unresectable\u002Fmetastatic solid tumor measurable by RECIST v1.1.\n* CRC: Part 1A, Part 2A-CRC, Part 1B, and Part 2B:\n\n  i) Locally advanced\u002Fmetastatic, recurrent, or unresectable CRC with adenocarcinoma histology and whose disease has progressed after systemic cancer therapy in the metastatic or adjuvant setting including 5-FU, irinotecan, and\u002For oxaliplatin (if available and not contraindicated).\n* NSCLC: Part 2A-NSCLC\u002FGC, 2L+ NSCLC:\n\n  i) Histologically confirmed NSCLC meeting stage criteria for Stage IIIB, Stage IV, or recurrent disease.\n\nii) Participants must have received and progressed on or after anti-PD-(L)1 therapy, if available.\n\n\\- GC: Part 2A-NSCLC\u002FGC, 2L+ GC: i) Participants must have received and then progressed or been intolerant to at least 1 standard treatment regimen in the advanced or metastatic setting (or have progressed within 6 months of adjuvant therapy).\n\nii) ECOG performance status of 0 or 1.\n\nExclusion Criteria:\n\n* History of anaphylactic reactions to irinotecan and\u002For bevacizumab.\n* Previously received therapy targeting CEACAM5.\n* Grade ≥3 ILD\u002Fpneumonitis.\n* Other protocol-defined Inclusion\u002FExclusion criteria apply.","ALL","18 Years",{"count":133,"type":134},360,"ESTIMATED","INTERVENTIONAL",[137,138],"PHASE1","PHASE2","This is a study of BMS-986490 as a monotherapy and in combination with bevacizumab in participants with select advanced solid tumors known to express CEACAM5.",[141],"Advanced Solid Tumors",[143,144,145],"Colorectal Cancer (CRC)","Non-small Cell Lung cancer (NSCLC)","Gastric Cancer (GC)","2026-07-01",{"date":148,"type":149},"2026-07-02","ACTUAL",{"date":151,"type":149},"2025-02-12",{"date":153,"type":134},"2029-12-09",{"name":5,"class":6},6]